Disease · MONDO_0010679
Trials145
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.
1 to 20 of 145
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03179631 | Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy | Phase 3 | 360 | 2026-03-10 | Muscular Dystrophy, Duchenne, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Disease, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn | ATALUREN | Its record names the disease | ClinicalTrials.gov |
| NCT01865084 | A Study of Tadalafil for Duchenne Muscular Dystrophy | Phase 3 | 331 | 2017-03-01 | Muscular Dystrophy, Duchenne | TADALAFIL | Its record names the disease | ClinicalTrials.gov |
| NCT01826487 | Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) | Phase 3 | 230 | 2020-08-04 | Muscular Dystrophy, Duchenne, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn | ATALUREN | Its record names the disease | ClinicalTrials.gov |
| NCT02090959 | An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy | Phase 3 | 219 | 2020-08-11 | Muscular Dystrophy, Duchenne, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn | ATALUREN | Its record names the disease | ClinicalTrials.gov |
| NCT01603407 | Finding the Optimum Regimen for Duchenne Muscular Dystrophy | Phase 3 | 196 | 2022-08-12 | Duchenne Muscular Dystrophy | DEFLAZACORT, PREDNISONE | Its record names the disease | ClinicalTrials.gov |
| NCT01254019 | A Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy | Phase 3 | 186 | 2019-01-28 | Muscular Dystrophies | DRISAPERSEN | Its record names the disease | ClinicalTrials.gov |
| NCT02851797 | Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy | Phase 3 | 179 | 2023-02-02 | Duchenne Muscular Dystrophy | GIVINOSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT00592553 | Phase 2B Study of PTC124 (Ataluren) in Duchenne/Becker Muscular Dystrophy (DMD/BMD) | Phase 2 | 174 | 2020-04-07 | Duchenne Muscular Dystrophy, Becker Muscular Dystrophy | ATALUREN | Its record names the disease | ClinicalTrials.gov |
| NCT00847379 | Phase 2B Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD) | Phase 2 | 173 | 2020-07-15 | Duchenne Muscular Dystrophy, Becker Muscular Dystrophy | ATALUREN | Its record names the disease | ClinicalTrials.gov |
| NCT03532542 | An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy | Phase 3 | 171 | 2024-09-19 | Duchenne Muscular Dystrophy | CASIMERSEN, GOLODIRSEN | Its record names the disease | ClinicalTrials.gov |
| NCT03039686 | Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy | Phase 2/3 | 166 | 2020-12-21 | Duchenne Muscular Dystrophy | TALDEFGROBEP ALFA | Its record names the disease | ClinicalTrials.gov |
| NCT03703882 | Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy | Phase 3 | 131 | 2022-06-21 | Muscular Dystrophy, Duchenne | EDASALONEXENT | Its record names the disease | ClinicalTrials.gov |
| NCT02310763 | A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy | Phase 2 | 121 | 2019-07-23 | Duchenne Muscular Dystrophy | DOMAGROZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03439670 | A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD) | Phase 2 | 121 | 2022-07-13 | Duchenne Muscular Dystrophy | VAMOROLONE | Its record names the disease | ClinicalTrials.gov |
| NCT02255552 | Study of Eteplirsen in DMD Patients | Phase 3 | 109 | 2020-07-01 | Duchenne Muscular Dystrophy (DMD) | ETEPLIRSEN | Its record names the disease | ClinicalTrials.gov |
| NCT04371666 | Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD) | Phase 3 | 98 | 2024-03-12 | Duchenne Muscular Dystrophy | PAMREVLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01557400 | Study of Ataluren for Previously Treated Participants With Nonsense Mutation Duchenne/Becker Muscular Dystrophy (nmDBMD) in Europe, Israel, Australia, and Canada | Phase 3 | 94 | 2020-11-25 | Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Dystrophinopathy | ATALUREN | Its record names the disease | ClinicalTrials.gov |
| NCT04060199 | Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53) | Phase 3 | 77 | 2024-12-11 | Duchenne Muscular Dystrophy | VILTOLARSEN | Its record names the disease | ClinicalTrials.gov |
| NCT04632940 | Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD | Phase 3 | 73 | 2024-08-26 | Duchenne Muscular Dystrophy | PAMREVLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01027884 | Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD) | Phase 3 | 65 | 2015-10-19 | Muscular Dystrophy, Duchenne, Ambulatory Care | IDEBENONE | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0010679/trials